New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD CompositionUnusual Whales·Jul 22 at 07:41 AMARTL-17.80%
Artelo analysis finds low-dose OTC CBD products miss therapeutic efficacy across 50-plus studiesPUBT·Jul 22 at 07:39 AMARTL-17.80%
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 | ARTL Stock NewsStockTitan·Jul 13 at 11:47 PMARTL-17.80%
Artelo Biosciences reports positive preclinical data for ART27.13 in paclitaxel-induced peripheral neuropathy modelPUBT·Jul 13 at 08:28 AMARTL-17.80%
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord InjuryUnusual Whales·Jul 1 at 07:44 AMARTL-17.80%
Artelo Biosciences reports positive preclinical data for ART26.12 in spinal cord injury neuropathic pain modelPUBT·Jul 1 at 07:42 AMARTL-17.80%
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026Unusual Whales·Jun 30 at 07:59 AMARTL-17.80%
Artelo Biosciences says Phase 1 study shows FABP5 inhibitor ART26.12 is well tolerated, with linear pharmacokineticsPUBT·Jun 29 at 07:45 AMARTL-17.80%
